OTIS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Otis Worldwide Corp is not a strong buy at the moment for a beginner investor with a long-term focus. While the company's financials show growth and hedge funds are increasing their positions, the technical indicators suggest a neutral to bearish short-term trend, and analyst sentiment is mixed with recent downgrades. Additionally, insider selling has surged significantly, which could indicate caution. The options data also reflects a bullish sentiment, but the lack of strong proprietary trading signals and the current pre-market price decline make it prudent to hold off on buying right now.
The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 42.59, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading below the pivot level of 91.526, with key support at 89.238. The pre-market price is down 0.70%, suggesting further weakness.
Hedge funds are significantly increasing their positions, with a 676.26% increase in buying activity over the last quarter.
The company reported strong financial growth in Q4 2025, with revenue up 3.29% YoY, net income up 10.98% YoY, and EPS up 13.10% YoY.
Insiders are selling heavily, with a 4363.40% increase in selling activity over the last month.
Analyst sentiment is mixed, with recent downgrades from JPMorgan and Barclays citing weaker guidance and sub-par organic profit growth.
The stock has a 70% chance of declining further in the short term, with projections of -1.1% in the next day and -11.17% in the next month.
In Q4 2025, Otis Worldwide reported revenue growth of 3.29% YoY to $3.796 billion, net income growth of 10.98% YoY to $374 million, and EPS growth of 13.10% YoY to $0.95. Gross margin also improved by 3.60% YoY to 30.22%.
Analyst sentiment is mixed. BNP Paribas recently initiated coverage with an Outperform rating and a $109 price target, while JPMorgan downgraded the stock to Neutral with a reduced price target of $98, citing weaker guidance and missed sales in Q4. Barclays also lowered its price target to $90, highlighting sub-par organic profit growth.
